Empowered Funds LLC Takes $319,000 Position in Haemonetics Co. (NYSE:HAE)

Empowered Funds LLC bought a new stake in Haemonetics Co. (NYSE:HAE - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,086 shares of the medical instruments supplier's stock, valued at approximately $319,000.

Several other institutional investors and hedge funds also recently made changes to their positions in HAE. Nisa Investment Advisors LLC grew its stake in Haemonetics by 124.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier's stock worth $92,000 after purchasing an additional 632 shares in the last quarter. KBC Group NV grew its position in shares of Haemonetics by 54.6% in the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after acquiring an additional 712 shares in the last quarter. iSAM Funds UK Ltd bought a new stake in shares of Haemonetics in the 3rd quarter valued at approximately $204,000. CWC Advisors LLC. acquired a new stake in shares of Haemonetics during the 3rd quarter valued at approximately $231,000. Finally, Versor Investments LP raised its position in shares of Haemonetics by 9.1% during the 3rd quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier's stock valued at $289,000 after acquiring an additional 300 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on HAE shares. Raymond James reiterated a "strong-buy" rating and set a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Barrington Research lowered their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a report on Friday, February 7th. StockNews.com downgraded Haemonetics from a "buy" rating to a "hold" rating in a report on Saturday, February 15th. JPMorgan Chase & Co. began coverage on Haemonetics in a research note on Friday, December 6th. They set an "overweight" rating and a $116.00 price objective for the company. Finally, Needham & Company LLC cut their target price on Haemonetics from $112.00 to $108.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $101.67.

Haemonetics Price Performance

Shares of HAE stock traded down $0.47 during midday trading on Friday, reaching $62.98. 986,273 shares of the company were exchanged, compared to its average volume of 1,030,576. The company's 50 day moving average price is $72.61 and its two-hundred day moving average price is $76.66. The company has a market cap of $3.16 billion, a P/E ratio of 24.79, a PEG ratio of 1.11 and a beta of 0.39. Haemonetics Co. has a 12 month low of $58.80 and a 12 month high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97.

Haemonetics (NYSE:HAE - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, sell-side analysts expect that Haemonetics Co. will post 4.55 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.